Delivery of wild-type Rbl2/p130 gene may revert malignant phenotype in various cancer types [10] including human cervix carcinoma (C33A)[11]; T98G human glioblastoma [9]; nasopharyngeal carcinoma and Saos-2 human osteosarcoma cells[3, 9]. This evidence concerns the gene RBL2 and nasopharyngeal carcinoma.